McIlrath & Eck’s CRISPR Therapeutics CRSP Stock Holding History

McIlrath & Eck’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-31	Closed	-$1.46K	–	987
2024 Q3	$1.46K	Hold	31	–	–	﹤0.01%	885
2024 Q2	$1.67K	Hold	31	–	–	﹤0.01%	837
2024 Q1	$2.11K	Hold	31	–	–	﹤0.01%	817
2023 Q4	$1.94K	Hold	31	–	–	﹤0.01%	807
2023 Q3	$1.41K	Hold	31	–	–	﹤0.01%	794
2023 Q2	$1.74K	Hold	31	–	–	﹤0.01%	792
2023 Q1	$1.4K	Hold	31	–	–	﹤0.01%	814
2022 Q4	$1.26K	Hold	31	–	–	﹤0.01%	781
2022 Q3	$2K	Hold	31	–	–	﹤0.01%	751
2022 Q2	$2K	Hold	31	–	–	﹤0.01%	732
2022 Q1	$2K	Hold	31	–	–	﹤0.01%	723
2021 Q4	$2K	Hold	31	–	–	﹤0.01%	714
2021 Q3	$3K	Hold	31	–	–	﹤0.01%	685
2021 Q2	$5K	Hold	31	–	–	﹤0.01%	616
2021 Q1	$4K	Buy	+31	New	+$4.68K	﹤0.01%	612

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

McIlrath & Eck's CRSP Position: Q4 2024 in Review

McIlrath & Eck sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 31 shares — an estimated $1.46K sold.

McIlrath & Eck first reported a position in CRSP in Q1 2021 and held it in 15 quarters. The position peaked at $5K in Q2 2021. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

McIlrath & Eck reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
McIlrath & Eck sold 31 CRISPR Therapeutics shares in Q4 2024, an estimated $1.46K.
McIlrath & Eck first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 15 quarters.
McIlrath & Eck's CRISPR Therapeutics position peaked at $5K in Q2 2021.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on McIlrath & Eck's 13F filing for Q4 2024, filed 18 Feb 2025.